Abstract
The phase 3 ALPINE trial (NCT03734016) compared the efficacy and safety of ibrutinib, a first-generation Bruton's tyrosine kinase (BTK) inhibitor, with zanubrutinib, a novel highly selective BTK inhibitor, in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The study aimed to conduct a budget impact analysis to estimate the incremental costs associated with using zanubrutinib in CLL/SLL patients from the US payer perspective.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
